Ramelteon: A new approach to managing insomnia

Future Neurology

Volumn 3, Issue 1, 2008, Pages 9-18

  Ebrahim, Irshaad ^a  

^a The London Sleep Centre   (United Kingdom)

Author keywords

Chronic insomnia; Circadian rhythm; Depression; Melatonin receptor agonist; Ramelteon; Sleep promotor; Sleep wake

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450; CYTOKINE RECEPTOR; DEXTROMETHORPHAN; DIGOXIN; ESCITALOPRAM; ESZOPICLONE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; HYPNOTIC SEDATIVE AGENT; KETOCONAZOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MIDAZOLAM; NEUROLEPTIC AGENT; NEUROPEPTIDE RECEPTOR; OMEPRAZOLE; PLACEBO; RAMELTEON; RIFAMPICIN; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BEDTIME DOSAGE; BODY EQUILIBRIUM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; ESTROGEN BLOOD LEVEL; FATIGUE; FIRST PASS EFFECT; HUMAN; HYDROCORTISONE BLOOD LEVEL; INFLUENZA; INSOMNIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MANAGED CARE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MOTOR DYSFUNCTION; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR PERFORMANCE; REPRODUCTION; SEXUAL FUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP TIME; SOMNOLENCE; STRUCTURE ANALYSIS; TESTOSTERONE BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WITHDRAWAL SYNDROME;

EID: 37649019587     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.1.9     Document Type: Article

References (55)

1. Morin AK, Jarvis CI, Lynch AM: Therapeutic options for sleep-maintenance and sleep-onset insomnia. Pharmacotherapy 27, 89-110 (2007).
2. Simon GE, VonKorff M: Prevalence, burden, and treatment of insomnia in primary care. Am. J. Psychiatry 154, 1417-1423 (1997).
3. National Institutes of Health: National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults. 13-15 June, 2005. Sleep 28, 1049-1057 (2005).
4. Kamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. Am. J. Med. 119, 463-469 (2006).
5. Hajak G, SINE Study Group; study of insomnia in Europe: epidemiology of severe insomnia and its consequences in Germany. Eur. Arch. Psychiatry Clin. Neurosci 25, 49-56 (2001).
6. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ: Epidemiology of insomnia, depression, and anxiety. Sleep 28, 1457-1464 (2005).
7. Saper CB, Scammell TE, Lu J: Hypothalamic regulation of sleep and circadian rhythms. Nature 437, 1257-1263 (2005).
8. Zee PC, Manthena P: The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med. Rev. 11, 59-70 (2007).
9. Bellon A: Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? J. Psychiatr. Pract. 12, 229-243 (2006).
10. Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin. Ther. 28 1540-1555 (2006).
11. Laustsen G, Andersen M: Ramelteon (Rozerem™) a novel approach for insomnia treatment. Nurse Pract. 31, 52-55 (2006).
12. McGechan A, Wellington K: Ramelteon. CNS Drugs 19, 1057-1065 (2005).
13. Owen RT: Ramelteon: profile of a new sleep-promoting medication. Drugs Today (Barc). 42, 255-263 (2006).
14. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP: Drug insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat. Clin. Pract. Neurol. 3, 221-228 (2007).
15. Wurtman R: Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev. Neurother. 6, 957-964 (2006).
16. 2 receptor agonist. Neuropharmacology 48, 301-310 (2005).
17. 2 melatonin receptor agonist indicated for treatment of insomnia. J. Clin. Pharmacol, 46, 140-148 (2006).
18. Hibberd M, Stevenson SJ: A Phase-I open-label study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375) following a single oral dose in healthy male subjects (Abstract). Sleep 27(Suppl.), A54 (2004).
19. 2. J. Clin. Pharmacol. 47, 485-496 (2007)
20. Karim A, Tolbert D, Cao C, Zhao Z: Effect of food on the systemic exposure of ramelteon (TAK-375) following a single dose (Abstract). J. Clin. Pharmacol. 44, 1210 (2004).
21. Karim A, Tolbert D, Zhao Z: Single and multiple dose pharmacokinetic evaluation of ramelteon (TAK-375) in subjects with and without hepatic impairment (Abstract). J. Clin. Pharmacol. 44, 1210 (2004).
22. Tolbert D, Karim A, Zhao Z: Evaluation of the single and multiple dose pharmacokinetics of ramelteon (TAK-375) in subjects with and without renal impairment (Abstract). J. Clin. Pharmacol. 44, 1210 (2004).
23. Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/ MT2-receptor agonist, reduced latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28, 303-307 (2005).
24. Zammit G, Schwartz H, Roth T, Wright L, Sainati S, Zhang J: Phase III study of ramelteon in a first-night-effect model of transient insomnia. Sleep Med. 6S2, S50-S51 (2005).
25. Erman M, Sieden D, Zammit G et al.: An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 7, 17-24 (2006).
26. Zammit G, Erman M, Wang-Weigand S et al.: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J. Clin. Sleep Med. 3, 495-504 (2007).
27. Mini L, Wang-Weigand S, Zhang J, Kasten K: Reduction in sleep latency during 5 weeks of treatment with rameheon 8 mg versus placebo in patients with chronic insomnia (Abstract). Neurology 66, A9 (2006).
28. DeMicco M, Wang-Weigand S, Zhang J: Long-term therapeutic effects of ramelteon treatment in adults with chronic insomnia: a 1-year study (Abstract). Sleep 29, A234 (2006).
29. Wang-Weigand S, Mayer G, Roth-Schechter B: Long-term efficacy and safety of ramelteon 8 mg treatment in adults with chronic insomnia: results of a six-month, double-blind, placebo-controlled, polysomnography trial. Sleep Biol. Rhythm, 5, A156 (2007).
30. Roth T, Seidcn D, Wang-Weigand S, Zhang J: A 2-night, 3-period, cross-over study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr. Med. Pes. Opin 23, 1005-1014 (2007).
31. Roth T, Seiden D, Sainari S et al.: Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 7, 312-318 (2006).
32. Richardson G, Wang-Weigand S, Zhang J, DeMicco M: Long-term safety of ramelteon treatment in adults with chronic insomnia (Abstract). Sleep 29, A233 (2006).
33. Richardson GS, Wang-Weigand S, Sainati S, Demissie S: Long-term effects of ramelreon on endocrine function in patients with chronic insomnia in a double-blind, placebo-controlled Phase III study (Abstract). Clin. Pharmacol. Ther. 79, P68 (2006).
34. Griffiths RR, Johnson MW: Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J. Clin. Psychiatry 66, 31-41 (2005).
35. Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative side effects. Arch. Gen. Psychiatry 63, 1149-1157 (2006).
36. Sainati S, Tsymbalov S, Demissie S, Roth T: Double-blind, placebo-controlled, two-way crossover study of ramelteon in subjects with mild to moderate chronic obstructive pulmonary disease (COPD) (Abstract). Sleep 28, A162 (2005).
37. Thapa P, Gideon P, Brockman K, Fought R, Ray W: Clinical and biomechanical measures of balance as fall predictors in ambulatory nursing home residents. J. Genolotol. 51A, M239-M246 (1996).
38. Jarnlo GB: Hip fracture patients. Background factors and function. Scand. J. Rehabil. Med. Suppl. 24, 1-31 (1991).
39. Hajak G, Ebrahim I, Hibberd M, Vincent S: Ramelteon, unlike zolpiclone, has no effect on body sway at peak plasma levels in insomnia patients (Abstract). Sleep 30, A245 (2007).
40. Tolbert D, Karim A, Johnson J, Cao C, Zhao Z, Sainati SM: Two-period crossover study to assess the drug interaction between ramelteon (TAK-375) and theophylline in healthy adults (Abstract). Sleep 27, A48 (2004).
41. Tolbert D, Karim A, Cao C, Munsaka M, Copa A: An open-label, randomized, multiple-dose, crossover study to assess the steady-state drug-drug interaction of omeprazole with ramelteon (TAK-375) in healthy men and women (Abstract). AAPS J. 6(4), R6199 (2004).
42. Tolbert D, Karim A, Cao C, Zhao Z, Johnson J, Sainati SM: Study to assess drug interaction between ramelteon (TAK-375) and dextromethorphan in healthy adults (Abstract). Sleep 27(Suppl.), A50 (2004).
43. Karim A, Tolbert D, Cao C, Zhao Z, Sainati SM: The effect of multiple doses of ramelteon (TAK-375) on the single-dose pharmacokinetic profile of midazolam in healthy adult subjects (Abstract). Sleep 27, A47-A48 (2004).
44. Karim A, Tolbert D, Cao C, Zhao Z, Harris S: An open-label assessment of the pharmacokinetics and pharmacodynamics of warfarin in the presence of multiple doses of ramelteon (TAK-375) in healthy female and male subjects. AAPS J. 6(4), R6198 (2004).
45. 2 receptor agonist, in healthy adults (Abstract). Sleep 29, A237-A238 (2006).
46. Tolbert D, Karim A, Cao C, Munsaka M, Hunt T: Multiple-dose study to assess the effect of ramelteon (TAK-375) on the pharmacokinetics of digoxin in healthy subjects (Abstract). AAPS J. 6(4), R6195 (2004).
47. Tolbert D, Karim A. Demissie S: Phase I study to evaluated the short-term effects of ramelteon (TAK-375) on endocrine function in healthy adult subjects (Abstract). Pharmacology 44, 1210 (2005).
48. Richardson G, Wang-Weigand S, Sainati S, Demissie S: A double-blind placebo-controlled Phase III study of the long-term effects of ramelteon on endocrine function in adults with chronic insomnia (Abstract). Sleep 29, A232 (2006).
49. Kryger M, Wang-Weigand S, Roth T: Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath 11, 159-164 (2007).
50. Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ: Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J. Affect. Disord. 42, 209-212 (1997).
51. Pigeon W, Hegel MT, Mackenzie T, Lyness JM, Sateia M, Perlis M: Insomnia as a risk for increased morbidity in depressed elderly subjects treated for depression: the IMPACT cohort (Abstract). Sleep 28, A307 (2005).
52. Lichstein KL, Wilson NM, Johnson CT: Psychological treatment of secondary insomnia. Psychology Aging 2, 232-240 (2000).
53. Rybarczyk B, Lopez M, Benson R, Alsten C, Stepanski E: Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychology Aging 17, 288-298 (2002).
54. Taylor DJ, Mallory LJ, Lichstein KL et al.: Comorbidity of chronic insomnia with medical problems. Sleep 30, 213-218 (2007).
55. Kupfer DJ: Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharm. 16, S639-S643 (2006).